CDMO News

Freudenberg Medical Invests $50M in New German Facility

  • Freudenberg Medical is investing over $50 million in a new production facility in Aachen, Germany, expanding its drug device combination products business.
  • The new facility will triple the company’s manufacturing footprint, serving as a hub for research, development, and production, with a focus on sustainability.

Freudenberg Medical, a global contract design and manufacturing (CDMO) partner to the medical device and biopharma industry, is making a substantial investment in its drug device combination products business. The company is investing more than $50 million in a new production facility in Aachen, Germany, a key life science hub.

The company’s portfolio has grown to include drug coating solutions for balloon catheters and stents, as well as hydrophilic coatings, since the acquisition of Hemoteq in 2015. This new facility not only expands the company’s capabilities but also reaffirms its roots in the region.

The new 130,000 sq. ft. facility in Alsdorf, near the existing site, will triple the company’s manufacturing footprint. Equipped with ISO Class 7 cleanrooms, laboratories, and offices, it will serve as a hub for research, development, and production, driving innovation in medical coatings.

Dr. Mark Ostwald, CEO of Freudenberg Medical, says, “The convergence of medical devices and drugs is inspiring a new generation of innovative products that fundamentally improve patients’ outcomes. With this innovation-driven investment, we are strengthening our position as a strategic partner to our customers, offering vertically integrated solutions along the entire supply chain.”

The company is also focusing on sustainability. The existing industrial building at the site is being converted to meet the highest medical technology as well as environmental and energy efficiency standards. A company-owned PV solar power plant will generate the energy needed to operate the site. Other sustainable features include charging stations for emission-free commuting, energy recovery from the exhaust air of the clean rooms for heating, and an existing heavy oil tank converted into a cistern for rainwater utilization.

The first employees have been working at the new site since April 2024 in a development cleanroom adjacent to the main building. The site will be fully occupied by the end of 2026. Recruitment for the 150 additional positions in operations and R&D has already begun. With a total area of 440,000 sq. ft., the site offers space for future expansion.

ELEARNING
Learn the essentials of successful biopharma outsourcing

Experience the future of contract manufacturing

Join us at CDMO Live, 7-8 May 2025 in Rotterdam for an exclusive live event dedicated to contract manufacturing partnerships. Apply for your ticket.

Sign up to our free weekly newsletter for all the latest contract manufacturing news.  Register here

ELEARNING

Learn the essentials of successful biopharma outsourcing

New eLearning course distils 100+ expert interviews into 10 engaging modules.

tick Overview of outsourcing trends 
tick Expert insights and case studies 
tick Helpful resources and quizzes

Who do you rate?
Recommend a Supplier

Help us find the most innovative and trusted suppliers in Pharma and Biotech.